Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olitigaltin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 known ✓ | P17931 | 20/20 | 1.00 |
| ▸ | LGALS1 | P09382 | 13/20 | 1.00 |
| ▸ | LGALS8 | O00214 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olitigaltin SCHEMBL18556517 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL19630648 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL15657272 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL19678765 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL17432857 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL19680604 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL23939583 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL19848047 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL17163850 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 | |
| Olitigaltin SCHEMBL17935223 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827666-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2023-11-28 | — | — | US | disclosed |
| US-20230014870-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-01-19 | — | — | US | disclosed |
| US-11377464-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2022-07-05 | — | — | US | disclosed |
| US-20220017558-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-01-20 | — | — | US | disclosed |
| US-20210380623-A1 | PRODRUG GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-12-09 | — | — | US | disclosed |
| EP-3896075-A1 | POLYMORPHIC FORMS AND PROCESS | Galecto Biotech AB (DK) | 2021-10-20 | — | — | EP | disclosed |
| US-20210284678-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-09-16 | — | — | US | disclosed |
| US-11046725-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2021-06-29 | — | — | US | disclosed |
| US-10988502-B2 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2021-04-27 | — | — | US | disclosed |
| US-10889610-B2 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2021-01-12 | — | — | US | disclosed |
| US-20190315793-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2019-10-17 | — | — | US | disclosed |
| US-10369136-B2 | Polymorphic forms and process | GALECTO BIOTECH AB (DK) | 2019-08-06 | — | — | US | disclosed |
| US-20190225638-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2019-07-25 | — | — | US | disclosed |
| US-10307403-B2 | Polymorphic forms and process | GALECTO BIOTECH AB (DK) | 2019-06-04 | — | — | US | disclosed |
| US-20190117627-A1 | POLYMORPHIC FORMS AND PROCESS | GALECTO BIOTECH AB (DK) | 2019-04-25 | — | — | US | disclosed |
| US-10253059-B2 | Hybrid galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2019-04-09 | — | — | US | disclosed |
| WO-2018011094-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2018-01-18 | — | — | WO | disclosed |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20170349622-A1 | NOVEL HYBRID GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | disclosed |
| WO-2017103109-A1 | POLYMORPHIC FORMS AND PROCESS | GALECTO BIOTECH AB (DK) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827666-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885LGALS8 7/4885 |
| US-10307403-B2 | Polymorphic forms and process | CYP11B1, CYP11B2, UGT1A1 | LGALS3 2312/4885LGALS1 1181/4885LGALS8 3196/4885 |
| US-20230014870-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS8 12/4885 |
| US-11377464-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | LGALS3 1/4885LGALS1 2/4885LGALS8 6/4885 |
| US-20210380623-A1 | PRODRUG GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS3BP | LGALS3 2/4885LGALS1 1/4885LGALS8 6/4885 |
| US-20190315793-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS8 8/4885 |
| US-20220017558-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS8 6/4885 |
| US-10889610-B2 | Alpha-D-galactoside inhibitors of galectins | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS8 8/4885 |
| US-10253059-B2 | Hybrid galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS8 8/4885 |
| US-20190117627-A1 | POLYMORPHIC FORMS AND PROCESS | CYP11B1, CYP11B2, UGT1A1 | LGALS3 2312/4885LGALS1 1181/4885LGALS8 3196/4885 |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS3, LGALS1, LGALS2 | LGALS3 1/4885LGALS1 2/4885LGALS8 6/4885 |
| US-11046725-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885LGALS8 7/4885 |
| US-20210284678-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS2, LGALS3BP | LGALS3 5/4885LGALS1 1/4885LGALS8 6/4885 |
| US-20190225638-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885LGALS8 8/4885 |
| US-20170349622-A1 | NOVEL HYBRID GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS8 8/4885 |
| US-10988502-B2 | Alpha-D-galactoside inhibitors of galectins | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885LGALS8 8/4885 |
| US-10369136-B2 | Polymorphic forms and process | CYP11B1, CYP11B2, UGT1A1 | LGALS3 2312/4885LGALS1 1181/4885LGALS8 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.